Bifunctional αHER2/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2+ gastric cancer

被引：23
作者：
Luo, Feifei [1 ,2 ,3 ]
Qian, Jiawen [3 ]
Yang, Jiao [3 ]
Deng, Yuting [3 ]
Zheng, Xiujuan [3 ]
Liu, Jie [1 ,2 ,3 ]
Chu, Yiwei [1 ,2 ,3 ]
机构：
[1] Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai 200032, Peoples R China
[2] Fudan Univ, Dept Immunol, Sch Basic Med Sci, Shanghai 200032, Peoples R China
[3] Fudan Univ, Biotherapy Res Ctr, Shanghai 200032, Peoples R China
来源：
CELL RESEARCH | 2016年 / 26卷 / 07期
关键词：
BISPECIFIC ANTIBODY; BLINATUMOMAB; THERAPY;
D O I：
10.1038/cr.2016.81
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：850 / 853
页数：4
相关论文
共 12 条
[1]   Tumor regression in cancer patients by very low doses of a T cell-engaging antibody [J].
Bargou, Ralf ;
Leo, Eugen ;
Zugmaier, Gerhard ;
Klinger, Matthias ;
Goebeler, Mariele ;
Knop, Stefan ;
Noppeney, Richard ;
Viardot, Andreas ;
Hess, Georg ;
Schuler, Martin ;
Einsele, Hermann ;
Brandl, Christian ;
Wolf, Andreas ;
Kirchinger, Petra ;
Klappers, Petra ;
Schmidt, Margit ;
Riethmueller, Gert ;
Reinhardt, Carsten ;
Baeuerle, Patrick A. ;
Kufer, Peter .
SCIENCE, 2008, 321 (5891) :974-977
[2]   Chimeric Antigen Receptor Therapy for Cancer [J].
Barrett, David M. ;
Singh, Nathan ;
Porter, David L. ;
Grupp, Stephan A. ;
June, Carl H. .
ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 :333-347
[3]   Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial [J].
Brentjens, Renier ;
Yeh, Raymond ;
Bernal, Yvette ;
Riviere, Isabelle ;
Sadelain, Michel .
MOLECULAR THERAPY, 2010, 18 (04) :666-668
[4]   Do CARs Need a Driver's License? Adoptive Cell Therapy with Chimeric Antigen Receptor-Redirected T Cells Has Caused Serious Adverse Events [J].
Buening, Hildegard ;
Uckert, Wolfgang ;
Cichutek, Klaus ;
Hawkins, Robert E. ;
Abken, Hinrich .
HUMAN GENE THERAPY, 2010, 21 (09) :1039-1042
[5]   Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma [J].
Choi, Bryan D. ;
Kuan, Chien-Tsun ;
Cai, Mingqing ;
Archer, Gary E. ;
Mitchell, Duane A. ;
Gedeon, Patrick C. ;
Sanchez-Perez, Luis ;
Pastan, Ira ;
Bigner, Darell D. ;
Sampson, John H. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (01) :270-275
[6]   Bispecific antibodies engage T cells for antitumor immunotherapy [J].
Choi, Bryan D. ;
Cai, Mingqing ;
Bigner, Darell D. ;
Mehta, Ankit I. ;
Kuan, Chien-Tsun ;
Sampson, John H. .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2011, 11 (07) :843-853
[7]   Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis [J].
Dong, Yiyu ;
Van Tine, Brian A. ;
Oyama, Toshinao ;
Wang, Patricia I. ;
Cheng, Emily H. ;
Hsieh, James J. .
CELL RESEARCH, 2014, 24 (11) :1354-1366
[8]   Bispecific T-cell engagers for cancer immunotherapy [J].
Huehls, Amelia M. ;
Coupet, Tiffany A. ;
Sentman, Charles L. .
IMMUNOLOGY AND CELL BIOLOGY, 2015, 93 (03) :290-296
[9]   Blinatumomab: A historical perspective [J].
Nagorsen, Dirk ;
Kufer, Peter ;
Baeuerle, Patrick A. ;
Bargou, Ralf .
PHARMACOLOGY & THERAPEUTICS, 2012, 136 (03) :334-342
[10]   Blinatumomab: First Global Approval [J].
Sanford, Mark .
DRUGS, 2015, 75 (03) :321-327
12